In patients who responded, ongoing Soliris therapy maintained benefits in daily activities and disease severity through 26 weeks of treatment1

Available data suggest that clinical response is usually achieved by 12 weeks of Soliris treatment2

Soliris response to treatment (n = 62)2,a

  • Responders: 63% (n = 39)1
  • Nonresponders: 37% (n = 23)1

aResponders were defined as patients who achieved at least a 3-point improvement in MG-ADL total score at 2 consecutive scheduled visits within 12 weeks of treatment with Soliris (note that for those who first responded at week 12, the response was confirmed at week 16).1

For patients who responded to Soliris, available data suggest that clinical response is usually achieved by 12 weeks of treatment.2

Soliris treatment arm subanalysis: responders vs nonresponders at 12 weeks1,b

Bar graph of MG-ADL activities of daily living data, mean change from baseline at week 26, for Soliris responders and Soliris nonresponders
Bar graph of QMG disease severity data, mean change from baseline at week 26, for Soliris responders and Soliris nonresponders
Bar graph of QMG disease severity data, mean change from baseline at week 26, for Soliris responders and Soliris nonresponders
Bar graph of MG-QoL15 quality of life, mean change from baseline at week 26, for Soliris responders and Soliris nonresponders

In patients who responded, ongoing Soliris therapy helped maintain benefits in daily activities and disease severity through 26 weeks of treatment.1

bResponders were defined as patients who achieved at least a 3-point improvement in MG-ADL total score at 2 consecutive scheduled visits within 12 weeks of treatment with Soliris (note that for those who first responded at week 12, the response was confirmed at week 16).1
cLeast-squares mean is based on an ANCOVA analysis model with change from baseline as a dependent variable and the following as terms: cohort, pooled MGFA randomization stratification variable, and score at baseline.1

The safety of Soliris in anti-AchR+ gMG was evaluated in patients in the REGAIN study.2

Learn More

Explore the range of patient improvement in activities of daily living (MG-ADL) of patients in the REGAIN study.

See the data

INDICATION & IMPORTANT SAFETY INFORMATION FOR SOLIRIS® (eculizumab)

INDICATION

Generalized Myasthenia Gravis (gMG)

Soliris is indicated for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

Life-threatening and fatal meningococcal infections have occurred in patients treated with Soliris. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early.

 

  • Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies.
  •  
  • Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of Soliris, unless the risks of delaying Soliris therapy outweigh the risk of developing a meningococcal infection. (See Serious Meningococcal Infections for additional guidance on the management of the risk of meningococcal infection)
  •  
  • Vaccination reduces, but does not eliminate, the risk of meningococcal infections. Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected.

 

Soliris is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the Soliris REMS, prescribers must enroll in the program. Enrollment in the Soliris REMS program and additional information are available by telephone: 1-888-SOLIRIS (1-888-765-4747) or at www.solirisrems.com.

 

Contraindications

Soliris is contraindicated in:

  • Patients with unresolved serious Neisseria meningitidis infection
  • Patients who are not currently vaccinated against Neisseria meningitidis, unless the risks of delaying Soliris treatment outweigh the risks of developing a meningococcal infection

 

Warnings and Precautions

 

Serious Meningococcal Infections

 

Risk and Prevention

 

See Boxed WARNING for additional information on serious meningococcal infections.

 

Life-threatening and fatal meningococcal infections have occurred in patients treated with Soliris. The use of Soliris increases a patient’s susceptibility to serious meningococcal infections (septicemia and/or meningitis).

 

Vaccinate for meningococcal disease according to the most current ACIP recommendations for patients with complement deficiencies. Revaccinate patients in accordance with ACIP recommendations, considering the duration of Soliris therapy.

 

Immunize patients without a history of meningococcal vaccination at least 2 weeks prior to receiving the first dose of Soliris. If urgent Soliris therapy is indicated in an unvaccinated patient, administer meningococcal vaccine(s) as soon as possible and provide patients with 2 weeks of antibacterial drug prophylaxis.

 

The benefits and risks of antibiotic prophylaxis for prevention of meningococcal infections in patients receiving Soliris have not been established.

 

Vaccination reduces, but does not eliminate, the risk of meningococcal infections.

 

Closely monitor patients for early signs and symptoms of meningococcal infection, and evaluate patients immediately if an infection is suspected. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. Discontinue Soliris in patients who are undergoing treatment for serious meningococcal infections.

 

REMS

Because of the risk of meningococcal infections, Soliris is available only through a restricted program under a REMS. Under the Soliris REMS, prescribers must enroll in the program.

 

Prescribers must counsel patients about the risk of meningococcal infection, provide the patients with the REMS educational materials, and ensure patients are vaccinated with meningococcal vaccine(s).

 

Other Infections

Serious infections with Neisseria species (other than N. meningitidis), including disseminated gonococcal infections, have been reported.

 

Soliris blocks terminal complement activation; therefore, patients may have increased susceptibility to infections, especially with encapsulated bacteria. Additionally, Aspergillus infections have occurred in immunocompromised and neutropenic patients. Children treated with Soliris may be at increased risk of developing serious infections due to Streptococcus pneumoniae and Haemophilus influenzae type b (Hib). Administer vaccinations for the prevention of Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) infections according to ACIP guidelines. Use caution when administering Soliris to patients with any systemic infection.

 

Infusion Reactions

Administration of Soliris may result in infusion reactions, including anaphylaxis or other hypersensitivity reactions. In clinical trials, no patients experienced an infusion reaction that required discontinuation of Soliris. Interrupt Soliris infusion and institute appropriate supportive measures if signs of cardiovascular instability or respiratory compromise occur.

 

Adverse Reactions

The most frequently reported adverse reaction in the gMG placebo-controlled clinical trial (≥10%) is: musculoskeletal pain.

 

Please see full prescribing information for Soliris, including boxed WARNING regarding serious meningococcal infections.

Abbreviations: ANCOVA, analysis of covariance; anti-AchR+, acetylcholine receptor antibody positive; LOCF, last observation carried forward; MG, myasthenia gravis; MG-ADL, MG activities of daily living; MGC, MG composite; MGFA, Myasthenia Gravis Foundation of America; MG-QoL15, MG quality of life questionnaire; QMG, quantitative MG; SEM, standard error of the mean.

References

  1. Data on file. Alexion Pharmaceuticals, Inc.
  2. Soliris [prescribing information]. Boston, MA: Alexion Pharmaceuticals Inc; 2018.